产品
编 号：F479687
分子式：C22H14N4O3
分子量：382.37
分子式：C22H14N4O3
分子量：382.37
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 851095-32-4
产品详情
生物活性：
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM.
体内研究：
STX-0119 (160 mg/kg; oral gavage; daily for 4 days) inhibits SCC-3 tumor growth in mice.The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 μg/mL (>260 μM), even at 8 h after administration.Animal Model:Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model
Dosage:160 mg/kg
Administration:Oral gavage, daily for 4 days
Result:Suppressed the growth of SCC-3 cells significantly on the fourth day.
体外研究：
STX-0119 (10-50 μM; 24 h) inhibits STAT3 dimerization through a direct interaction with the STAT3 protein and not via the modulation of upstream regulators such as JAK in HEK293 and MDA-MB-468 cells.STX-0119 (10-50 μM; 24 h) reduces the expression of STAT3 target proteins.
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC50 of 74 μM.
体内研究：
STX-0119 (160 mg/kg; oral gavage; daily for 4 days) inhibits SCC-3 tumor growth in mice.The plasma concentration of STX-0119 (160 mg/kg; oral gavage) is maintained at >100 μg/mL (>260 μM), even at 8 h after administration.Animal Model:Male BALB/cA-ν/ν nude mice, SCC-3 lymphoma xenograft model
Dosage:160 mg/kg
Administration:Oral gavage, daily for 4 days
Result:Suppressed the growth of SCC-3 cells significantly on the fourth day.
体外研究：
STX-0119 (10-50 μM; 24 h) inhibits STAT3 dimerization through a direct interaction with the STAT3 protein and not via the modulation of upstream regulators such as JAK in HEK293 and MDA-MB-468 cells.STX-0119 (10-50 μM; 24 h) reduces the expression of STAT3 target proteins.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备